The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CTXR | -82.98% | -94.49% | -44% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +244% |
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.04M | 21.7% |
| Market Cap | $17.77M | -80.9% |
| Market Cap / Employee | $0.77M | 0.0% |
| Employees | 23 | 0.0% |
| Net Income | -$9.20M | 13.0% |
| EBITDA | -$8.75M | 17.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.09M | -66.0% |
| Inventory | 17.2 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.77M | 808.4% |
| Short Term Debt | $1.11M | 373.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.83% | 1.1% |
| Return On Invested Capital | -38.41% | 0.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.41M | 35.4% |
| Operating Free Cash Flow | -$5.41M | 35.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.29 | 0.41 | 0.18 | 0.23 | -80.38% |
| Price to Tangible Book Value | 133.54 | -0.90 | -0.31 | -0.34 | -100.15% |
| Enterprise Value to EBITDA | -8.34 | -3.26 | -1.48 | -1.81 | -77.38% |
| Return on Equity | -48.6% | -52.9% | -60.1% | -53.4% | 27.92% |
| Total Debt | $0.26M | $0.20M | $0.93M | $1.88M | 488.00% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
